Treatment of attention-deficit/hyperactivity disorder

Details Treatment of attention-deficit/hyperactivity disorder Treatment of attention-deficit/hyperactivity disorder

1998-09-17

2000-04-04

Krass, Frederick

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

5142388, 5142395, A61K 31535

Patent

active

060461934

ABSTRACT:
Reboxetine is used to treat attention-deficit/hyperactivity disorder.

REFERENCES:
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4271160 (1981-06-01), Melloni et al.
patent: 5532268 (1996-07-01), Wong et al.
patent: 5658590 (1997-08-01), Heiligenstein et al.
patent: 5696168 (1997-12-01), Heiligenstein et al.
Harkin, et al., J. Psychopharmacol. (Oxford), Abstract, 1997, vol. 11, No. 3, Suppl. A39.
MEDLINE abstract 97312865, "Noradrenaline in Basic Models of Depression", Apr. 1997.
Eur. Neuropsychopharmacol., vol. 7, No. suppl 1, Apr. 1997, pp. s71-s73.
J. Clin. Psychiatry 1997;58 (suppl. 14) 4-29.
Am J Psychaitry 152:7, Jul. 1995.
Sychopharmacology Bulletin, p. 80 Venlafaxine Versus Stimulant Therapy in Patients with Dual Diagnoses of Attention-Deficit Disorder and Depression (1995).

Affiliated with

Also associated with

Rating

Treatment of attention-deficit/hyperactivity disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of attention-deficit/hyperactivity disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of attention-deficit/hyperactivity disorder will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-365310